Products & Pipeline
Anatara’s Anti-Obesity Program
Anatara Lifesciences is developing an oral product aimed at supporting weight reduction and sustainable weight management. This program is designed to complement existing obesity treatments and weight management strategies by addressing gaps in current management options.
Rebound weight gain following the discontinuation of pharmaceutical intervention remains a significant issue in obesity management. This can exacerbate health risks, such as the incidence of cardiovascular events and hormonal dysregulation, thereby compromising long-term desired outcomes.
Anatara’s program is focused on developing a product that may support long-term outcomes by targeting the body’s natural mechanisms for weight control. This approach aims to reduce the likelihood of weight cycling and its associated risks.
Stimulating Endogenous
GLP-1 Production
GLP-1 is a hormone involved in weight management through several mechanisms:
Reducing appetite and promoting satiety
Delaying gastric emptying to improve portion control
Enhancing insulin sensitivity for better metabolic stability
Anatara’s program aims to stimulate the body’s natural production of GLP-1, providing a potentially safer and more accessible alternative to current injectable therapies in weight reduction and control. This approach is also envisaged as an adjunctive treatment to sustain and support weight loss following the use of injectables to achieve a desired weight reduction goal.
Put simply, an individual with obesity may use injectable GLP-1 agonists to reduce weight to a more manageable level and then maintain a weight control programme with an oral product that has a similar mechanism of action while continuing on with lifestyle strategies (e.g. increased exercise, modified eating plans).
Key Characteristics
Oral Delivery
A non-invasive approach to improve compliance and accessibility
Reduced Side Effects
Targeting endogenous pathways for improved safety
Long-Term Weight Management
Designed to assist with weight management, especially rebound weight gain
Cost-Effective
Aiming to provide an affordable option for broader accessibility
Why is a new approach needed for the Overweight and Obese?
Obesity is a complex condition with multifactorial causes, and its management requires a comprehensive approach. Existing treatments have shown efficacy in weight reduction but come with limitations such as side effects and challenges related to long-term sustainability. In addition, particularly for the current use of GLP-1 receptor agonists, there are uncertainties with potential longer term side-effects, especially relating to metabolic considerations. Anatara’s program is focused on developing an oral product that may complement existing treatments in obesity management and assist the “overweight” by addressing these limitations.
The approach centres on stimulating the body’s natural production of GLP-1, a hormone involved in regulating appetite and metabolism, which could provide a potentially more accessible and sustainable solution for weight management.
The objective of Anatara’s anti-obesity project is to further research the development of a potential solution that could support long-term weight control, reduce the risk of rebound weight gain, and improve overall health outcomes without compromising safety. The project will enter the pre-clinical phase in early 2025, subject to the usual ethics approval pathway, details of which will be disclosed in due course.
Want to stay up to date with our trials and latest news?
Sign up here